Form 4: Arcutis Biotherapeutics Executive Sells Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., sold common stock totaling 28,750 shares in July 2025, pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported transactions involving the exercise of stock options and subsequent sale of common stock.
- On July 10, 2025, Burnett exercised options to acquire 23,000 shares of common stock at an exercise price of $0 and simultaneously sold 23,000 shares at a weighted average price of $15.0455.
- On July 14, 2025, Burnett exercised options to acquire an additional 5,750 shares of common stock at an exercise price of $0 and sold 5,750 shares at a weighted average price of $15.0702.
- All reported transactions were conducted under a Rule 10b5-1 trading plan adopted on December 12, 2024, which is set to conclude on February 27, 2026.
- Following these transactions, Burnett directly beneficially owns 115,468 shares of common stock and 172,500 stock options.
- The stock options exercised were granted on January 12, 2024, with an exercise price of $3.64, vesting monthly over four years, and expiring on January 12, 2034.
Sentiment
Score: 5
Explanation: The document reports routine insider stock transactions under a pre-arranged 10b5-1 plan, which is a neutral event in terms of company performance or outlook.
Positives
- The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned sales rather than reactive decisions, which can mitigate concerns about insider selling.
- The sales occurred at prices above $15.00 per share, indicating a favorable market price for the insider's disposition of shares.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.
Future Outlook
No forward-looking statements or guidance regarding the company's future performance or strategy are provided in this Form 4.
Industry Context
This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information relevant to broader industry trends or competitor analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Patrick Burnett granted power of attorney to the company's Chief Executive Officer, Chief Financial Officer, and General Counsel to prepare, execute, and file Forms 3, 4, and 5 with the SEC on his behalf. | 07/10/2025 | Streamlines the process for filing legally required insider trading reports, ensuring timely compliance with Section 16(a) of the Securities Exchange Act of 1934. |
Stakeholder Impact
- Shareholders: May note the insider selling, but the pre-arranged 10b5-1 plan suggests a systematic approach rather than a reaction to new information.
- Employees, Customers, Suppliers, Creditors: No direct impact from this filing.
Next Steps
- Continued transactions by Patrick Burnett under the Rule 10b5-1 trading plan until its scheduled end date of February 27, 2026.
- Further vesting of Patrick Burnett's remaining stock options until fully vested on January 12, 2028.
Key Dates
| Date | Description |
|---|---|
| 01/12/2024 | Stock options granted to Patrick Burnett, with vesting commencing on this date. |
| 12/12/2024 | Rule 10b5-1 trading plan adopted by Patrick Burnett. |
| 07/10/2025 | Date of first reported transactions (option exercise and sale of 23,000 shares); Power of Attorney executed. |
| 07/14/2025 | Date of second reported transactions (option exercise and sale of 5,750 shares); Form 4 signed. |
| 02/27/2026 | End date of the 10b5-1 trading plan. |
| 01/12/2028 | Date when 100% of the granted stock options will be fully vested and exercisable. |
| 01/12/2034 | Expiration date of the stock options. |
Keywords
Arcutis Biotherapeutics, ARQT, Form 4, insider trading, stock options, 10b5-1 plan, Patrick Burnett, executive, stock sale, option exercise, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.